EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Rallybio's enterprise value is $-53.17 Mil.
Rallybio's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 was $0.64 Mil. Therefore, Rallybio's EV-to-Revenue for today is -83.59.
The historical rank and industry rank for Rallybio's EV-to-Revenue or its related term are showing as below:
RLYB'
s EV-to-Revenue Range Over the Past 10 Years
Min: -133.07 Med: -55.71 Max: -31.83
Current: -83.59
During the past 6 years, the highest EV-to-Revenue of Rallybio was -31.83. The lowest was -133.07. And the median was -55.71.
RLYB's EV-to-Revenue is ranked better than 98.99% of 987
companies
in the Biotechnology industry
Industry Median: 6.76
vs RLYB: -83.59
As of today (2025-05-10), Rallybio's stock price is $0.293.
Rallybio's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $0.02. Therefore, Rallybio's PS Ratio for today is 19.53.
Rallybio EV-to-Revenue Historical Data
The historical data trend for Rallybio's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Rallybio's EV-to-Revenue
For the Biotechnology subindustry, Rallybio's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rallybio's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rallybio's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Rallybio's EV-to-Revenue falls into.
Rallybio's current Enterprise Value is $-53.17 Mil.
Rallybio's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.64 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rallybio's share price for today is $0.293.
Rallybio's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.02.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rallybio EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Rallybio's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RLYB has been successfully added to your 